Government funding should prioritize research into non-pharmaceutical ED treatments, such as improved lifestyle interventions and advanced therapies like gene therapy and stem cell regeneration. This diversification reduces reliance on medication and addresses underlying health issues contributing to ED.
Investing in broader public health campaigns promoting healthy lifestyles–diet, exercise, stress management–can significantly reduce ED prevalence, lessening the long-term financial burden on healthcare systems. These campaigns should target younger demographics to prevent ED onset.
Data transparency and robust clinical trials are paramount. Government oversight ensures rigorous testing and unbiased evaluation of new treatments, building public trust and preventing premature market entry of ineffective or unsafe options. This includes clear reporting of funding sources and trial results.
Expanding access to affordable ED treatments is critical. Government policies should aim to lower the cost of existing medications and make new treatments available to all socioeconomic groups, fostering health equity. This could involve price negotiation or subsidies.
International collaboration on research and development can accelerate progress. Sharing data and resources globally leads to faster development of innovative solutions and broader access to effective treatments worldwide.
